Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Profit After Tax: 2019-2024

Historic Profit After Tax for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$105.3 million.

  • C4 Therapeutics' Profit After Tax fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 12.87%. This contributed to the annual value of -$105.3 million for FY2024, which is 20.52% up from last year.
  • As of FY2024, C4 Therapeutics' Profit After Tax stood at -$105.3 million, which was up 20.52% from -$132.5 million recorded in FY2023.
  • Over the past 5 years, C4 Therapeutics' Profit After Tax peaked at -$66.3 million during FY2020, and registered a low of -$132.5 million during FY2023.
  • Over the past 3 years, C4 Therapeutics' median Profit After Tax value was -$128.2 million (recorded in 2022), while the average stood at -$122.0 million.
  • In the last 5 years, C4 Therapeutics' Profit After Tax plummeted by 94.54% in 2020 and then increased by 20.52% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Profit After Tax stood at -$66.3 million in 2020, then fell by 26.48% to -$83.9 million in 2021, then crashed by 52.80% to -$128.2 million in 2022, then declined by 3.35% to -$132.5 million in 2023, then rose by 20.52% to -$105.3 million in 2024.